Hainan Zhongwang Medical Technology Development

Hainan Zhongwang Medical Technology Development is a Chinese pharmaceutical and biotechnology company founded in 2022 that focuses on new drug development and advanced formulations. The company's research and development efforts are primarily centered on small molecule therapeutics targeting nervous system diseases and endocrinology/metabolic disorders. Its pipeline features novel candidates such as LPC-007, which has received IND approval for primary Parkinson's disease, and LPC-013, which is at the IND application stage. Additionally, the company develops improved generic formulations, having completed human bioequivalence trials for products like brexpiprazole oral disintegrating films, ursodeoxycholic acid oral suspensions, and metformin/empagliflozin combination tablets.